HMGCR and ductal breast carcinoma in situ: Because statins inhibit the activity of HMG-CoA reductase, we next investigated whether targeting this pathway with fluvastatin impairs the growth of breast preneoplastic (MCF10.AT1) and DCIS (MCF10.DCIS) cells.